DNA Damage and Repair Biomarkers of Immunotherapy Response.
暂无分享,去创建一个
[1] L. Alexandrov,et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas , 2017, The Journal of pathology.
[2] C. Zahnow,et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[3] P. A. Futreal,et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.
[4] G. Hortobagyi,et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.
[5] S. Elledge,et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.
[6] Catherine J. Wu,et al. Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations , 2016, Gynecologic oncology reports.
[7] K. Harrington,et al. Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers , 2016 .
[8] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[9] Christopher A. Miller,et al. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. , 2016, Cancer discovery.
[10] S. Cairo,et al. Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents , 2016, Oncotarget.
[11] L. Zitvogel,et al. Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.
[12] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[13] M. Salto‐Tellez,et al. Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer , 2016, Journal of the National Cancer Institute.
[14] M. Berger,et al. Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Swisher,et al. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies , 2016, Clinical Cancer Research.
[16] D. Merico,et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Zhijian J. Chen,et al. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.
[18] S. Demaria,et al. Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.
[19] Jun S. Liu,et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.
[20] L. Garraway,et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. , 2016, JAMA oncology.
[21] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[22] Randal J. Kaufman,et al. The unfolded protein response in immunity and inflammation , 2016, Nature Reviews Immunology.
[23] G. Freeman,et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. , 2016, JCI insight.
[24] M. Kortylewski,et al. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. , 2016, Cell reports.
[25] Jun S. Liu,et al. Landscape of tumor-infiltrating T cell repertoire of human cancers , 2016, Nature Genetics.
[26] Satoru Miyano,et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.
[27] K. Kelly,et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. , 2016 .
[28] R. Kuick,et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer , 2016, Cell.
[29] V. Hornung,et al. Cre-dependent DNA recombination activates a STING-dependent innate immune response , 2016, Nucleic acids research.
[30] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[31] M. Stratton,et al. Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.
[32] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[33] J. D. Del Valle,et al. Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells. , 2016, Cancer research.
[34] Werner Meier,et al. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy , 2016, Cancer.
[35] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[36] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[37] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[38] Lauren L. Ritterhouse,et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.
[39] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[40] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[41] A. Snyder,et al. Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.
[42] Ian Tomlinson,et al. A panoply of errors: polymerase proofreading domain mutations in cancer , 2016, Nature Reviews Cancer.
[43] Alan Ashworth,et al. BRCAness revisited , 2016, Nature Reviews Cancer.
[44] Adam D. Thomas,et al. DNA damage and the balance between survival and death in cancer biology , 2015, Nature Reviews Cancer.
[45] P. Jeggo,et al. DNA repair, genome stability and cancer: a historical perspective , 2015, Nature Reviews Cancer.
[46] Lauren L. Ritterhouse,et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.
[47] F. Martinon,et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity , 2015, Proceedings of the National Academy of Sciences.
[48] G. Barber. STING: infection, inflammation and cancer , 2015, Nature Reviews Immunology.
[49] L. Zitvogel,et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 , 2015, Science.
[50] M. O’Connor,et al. Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.
[51] Di Chen,et al. IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells , 2015, PloS one.
[52] A. Rust,et al. Adenoma development in familial adenomatous polyposis and MUTYH‐associated polyposis: somatic landscape and driver genes , 2015, The Journal of pathology.
[53] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[54] Jorge Sabbaga,et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.
[55] C. Drake,et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.
[56] K. Cibulskis,et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.
[57] Michael S. Goldberg,et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.
[58] T. Schumacher,et al. Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. , 2015, Cancer cell.
[59] P. Gimotty,et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer , 2015, Cancer Immunology Research.
[60] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[61] S. Demaria,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.
[62] T. Aparicio,et al. PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .
[63] Michael S. Goldberg,et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model , 2015, Cancer Immunology Research.
[64] A. Khanna. DNA damage in cancer therapeutics: a boon or a curse? , 2015, Cancer research.
[65] A. Ng,et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab , 2015, Oncoimmunology.
[66] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[67] George E. Katibah,et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.
[68] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[69] L. Emens,et al. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.
[70] J. Castle,et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.
[71] C. Scott,et al. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] P. Klenerman,et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer , 2015, Clinical Cancer Research.
[73] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[74] Mads Thomassen,et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. , 2015, JAMA.
[75] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[76] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[77] A. Kröger,et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. , 2015, Immunity.
[78] A. D’Andrea,et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. , 2015, Cancer research.
[79] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[80] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[81] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[82] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[83] Michael R Stratton,et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.
[84] C. Drake,et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.
[85] E. Janssen,et al. STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells , 2014, The Journal of Immunology.
[86] D. Lambrechts,et al. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.
[87] Z. Modrušan,et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.
[88] Ying Wang,et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.
[89] M. Delorenzi,et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.
[90] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[91] G. Barber,et al. Inflammation-driven carcinogenesis is mediated through STING , 2014, Nature Communications.
[92] I. Stratford,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.
[93] G. Garinis,et al. DNA damage and innate immunity: links and trade-offs. , 2014, Trends in immunology.
[94] S. Gabriel,et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.
[95] P. Newell,et al. TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models , 2014, Cancer Immunology Research.
[96] K. Cibulskis,et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. , 2014, Blood.
[97] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[98] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[99] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[100] F. Couch,et al. Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer , 2014, Journal of the National Cancer Institute.
[101] S. Ferrone,et al. Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .
[102] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[103] S. Demaria,et al. An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.
[104] X. Matías-Guiu,et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. , 2013, Critical reviews in oncology/hematology.
[105] N. McGranahan,et al. The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.
[106] Jason B. Williams,et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.
[107] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[108] V. Hornung,et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.
[109] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[110] I. Dick,et al. Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.
[111] Jiri Bartek,et al. Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.
[112] K. Ishii,et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking , 2013, Proceedings of the National Academy of Sciences.
[113] J. Taube,et al. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.
[114] S. Demaria,et al. Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..
[115] W. McBride,et al. Regulatory T Cells in Radiotherapeutic Responses , 2012, Front. Oncol..
[116] M. van den Broek,et al. Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation , 2012, The Journal of Immunology.
[117] M. Meyerson,et al. Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential , 2012, Science.
[118] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[119] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[120] J. Neal,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] M. de Perrot,et al. CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma , 2012, Molecular Cancer Therapeutics.
[122] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[123] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[124] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[125] S. Pestka,et al. Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells , 2012, PloS one.
[126] Sohrab P Shah,et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma , 2012, Modern Pathology.
[127] Gord Glendon,et al. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .
[128] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[129] F. Di Virgilio,et al. Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.
[130] N. Reich,et al. The DNA Damage Response Induces IFN , 2011, The Journal of Immunology.
[131] R. Schreiber,et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.
[132] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[133] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[134] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[135] A. Aboussekhra,et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.
[136] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] J. Wolchok,et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. , 2010, Blood.
[138] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[139] J. Hoeijmakers. DNA damage, aging, and cancer. , 2009, The New England journal of medicine.
[140] J. Tschopp,et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.
[141] G. Shurin,et al. Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism1 , 2009, The Journal of Immunology.
[142] Matt van de Rijn,et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.
[143] V. Sondak,et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] S. Xiong,et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. , 2008, Clinical immunology.
[145] N. Kawashima,et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1 , 2008, The Journal of Immunology.
[146] S. Steinberg,et al. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.
[147] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[148] R. Ward,et al. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer , 2006, British Journal of Cancer.
[149] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[150] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[151] L. Zitvogel,et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.
[152] Roman K. Thomas,et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. , 2005, Blood.
[153] J. Witjes,et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. , 2005, The Journal of urology.
[154] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[155] T. Ørntoft,et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.
[156] J. Schlom,et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.
[157] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[158] J. Schlom,et al. Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.
[159] B. Quesnel,et al. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells , 2004, Leukemia.
[160] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[161] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[162] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[163] Daniel J Sargent,et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.
[164] C. N. Coleman,et al. Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy , 2003, The Journal of Immunology.
[165] W. Symmans,et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[166] T. Smyrk,et al. Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.
[167] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[168] Teruhiko Yoshida,et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. , 1999, Gastroenterology.
[169] R. Dummer,et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[170] D. Hallahan,et al. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. , 1996, Cancer research.
[171] D. Hallahan,et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[172] J. Le Bourgeois,et al. [Whole body irradiation]. , 1989, Pathologie-biologie.
[173] S. Order. The effects of therapeutic irradiation on lymphocytes and immunity , 1977, Cancer.
[174] D. Kingsley. An interesting case of possible abscopal effect in malignant melanoma. , 1975, The British journal of radiology.
[175] Mole Rh. Whole body irradiation; radiobiology or medicine? , 1953 .
[176] S. Jackson,et al. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. , 2017, Cancer discovery.
[177] A. D’Andrea,et al. Repair Pathway Choices and Consequences at the Double-Strand Break. , 2016, Trends in cell biology.
[178] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.
[179] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.
[180] T. Lynch,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[181] A. McCullough. Comprehensive molecular characterization of human colon and rectal cancer , 2013 .
[182] A. Melcher,et al. T-cell responses to survivin in cancer patients undergoing radiation therapy , 2008 .
[183] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[184] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .
[185] J. Ward. Nature of Lesions Formed by Ionizing Radiation , 1998 .